David B Yaden
Overview
Explore the profile of David B Yaden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiwari P, Berghella A, Sayali C, Doss M, Barrett F, Yaden D
Psychedelic Med (New Rochelle)
. 2025 Mar;
1(2):74-86.
PMID: 40046726
Background: Emerging literature suggests that classic psychedelics may have efficacy in treating mood and substance use disorders in humans. This has raised questions regarding the primary therapeutic mechanism of these...
2.
Ehrenkranz R, Agrawal M, Penberthy J, Yaden D
Int Rev Psychiatry
. 2025 Feb;
36(8):879-890.
PMID: 39980217
Prolonged Grief Disorder (PGD) is distinct from yet related to non-pathologic grief, depression, addiction, and Post-Traumatic Stress Disorder (PTSD) with a prevalence of up to 10% in bereaved populations. Hallmarks...
3.
Cheung K, Propes C, Jacobs E, Earp B, Yaden D
Int Rev Psychiatry
. 2025 Feb;
36(8):891-901.
PMID: 39980216
A number of organizations have developed or are developing psychedelic integration groups, held in person or online. In parallel, there have been calls to make enhanced integration available in the...
4.
Goldy S, Hendricks P, Keltner D, Yaden D
Int Rev Psychiatry
. 2025 Feb;
36(8):908-919.
PMID: 39980212
In this review, we discuss psychedelics' acute subjective and persisting therapeutic effects, outline the science of positive emotions, and highlight the value in considering distinct positive emotions in psychedelic science....
5.
6.
Cheung K, Earp B, Patch K, Yaden D
Am J Bioeth
. 2025 Jan;
25(1):16-28.
PMID: 39804307
When used clinically, psychedelics may appear unusual or even unique when compared to more familiar or long-standing medical interventions, prompting some to suggest that the ethical issues raised may likewise...
7.
Goldy S, Du B, Rohde J, Nayak S, Strickland J, Ehrenkranz R, et al.
J Psychopharmacol
. 2024 Nov;
:2698811241292951.
PMID: 39610363
Background: As classic psychedelics' therapeutic potential is studied and their popularity continues to rise, it is important to establish their relative risks and benefits. Previous surveys have tended to use...
8.
Associations between psychedelic use and cannabis use disorder in a nationally representative sample
Zech J, Yaden D, Jones G
Drug Alcohol Depend
. 2024 Nov;
266:112502.
PMID: 39586127
Background: Cannabis Use Disorder (CUD) is an increasingly prevalent disorder affecting millions of Americans each year. Psychedelic compounds have recently been investigated for their therapeutic potential in treating substance use...
9.
Buyukbabani M, Earp B, Hannikainen I, Barba T, Mihailov E, Yaden D, et al.
AJOB Neurosci
. 2024 Oct;
15(4):239-243.
PMID: 39423059
No abstract available.
10.
Hinkle J, Graziosi M, Nayak S, Yaden D
JAMA Psychiatry
. 2024 Sep;
81(12):1225-1235.
PMID: 39230883
Importance: A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its application to new populations and indications. Objective: To assess adverse events (AEs)...